Itraconazole
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial fungal infections including difficult-to-treat dermatophytoses and onychomycoses. Furthermore, shortened treatment regimens have proven to be effective, ranging from 1-day treatment for vaginal candidosis to 1-week pulse therapy per month, for 2-4 months, in onychomycosis and follicular dermatophytosis. Clinical experience with itraconazole in the treatment of deep mycoses is less comprehensive. However, results in systemic candidosis, sporotrichosis, blastomycosis, paracoccidioiodomycosis, certain types of histoplasmosis and aspergillosis are extremely encouraging. Itraconazole is less effective in the treatment of chromomycosis and coccidioidomycosis. Nevertheless, considering the refractory nature of these diseases, itraconazole has proven to be a valuable addition to the antifungal drugs currently available for treatment. Itraconazole has been well-tolerated with doses of up to 400 mg/day being generally free of serious adverse effects. However, a potential for drug interactions exists, mediated through the cytochrome P450 enzyme 3A4 system, which should be considered when itraconazole is used as part of a multi-drug regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Menichetti, F., Del Favero, A., Martino, P., Bucaneve, G., Micozzi, A., Girmenia, C., Barbabietola, G., Pagano, L., Leoni, P., Specchia, G., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515129 · Cited by 244 · cited 1×
“In addition, both the capsule [110] and the new oral solution [111,112] formulations of itraconazole have been shown in randomised, placebo-control led, double-blind trials to provide effective and well-tolerated prophylaxis in neutropenic cancer patients.”
Rhabdomyolysis from the Coadministration of Lovastatin and the Antifungal Agent Itraconazole
Lees, R. S., & Lees, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331015 · Cited by 136
Itraconazole: pharmacology, clinical experience and future development
De Beule, K. (1996) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(95)00043-7 · Cited by 96
Zhou, H., Goldman, M., Wu, J., Woestenborghs, R., Hassell, A. E., Lee, P., Baruch, A., Pesco‐Koplowitz, L., Borum, J., & Wheat, L. J. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04465.x · Cited by 60
Cited by
Cyclodextrin-based pharmaceutics: past, present and future
Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 1,996
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Emerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
Li, C.-L., Fang, Z.-X., Wu, Z., Hou, Y.-Y., Wu, H.-T., & Liu, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113616 · Cited by 46
RetractedKast, R. E. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030153 · Cited by 5
Metadata
- Authors
- Piérard, G., Arrese, J., & Piérard-Franchimont, C.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2000-01
- Volume
- 1
- Issue
- 2
- Pages
- 287-304
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W4249295016
- Cited by
- 92
- References
- 4
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Itraconazole. https://app.cochat.ai/papers/10.1517/14656566.1.2.287
- The paper
- Piérard, G., Arrese, J., & Piérard-Franchimont, C. (2000). Itraconazole. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.1.2.287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.